0001725160-22-000142.txt : 20220801 0001725160-22-000142.hdr.sgml : 20220801 20220801172817 ACCESSION NUMBER: 0001725160-22-000142 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220801 FILED AS OF DATE: 20220801 DATE AS OF CHANGE: 20220801 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Paul Andrea CENTRAL INDEX KEY: 0001863130 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39263 FILM NUMBER: 221125971 MAIL ADDRESS: STREET 1: 65 HAYDEN AVENUE STREET 2: 2ND FLOOR CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Zentalis Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001725160 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 823607803 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1359 BROADWAY, SUITE 1710 CITY: NEW YORK STATE: NY ZIP: 10018 BUSINESS PHONE: (212) 433-3791 MAIL ADDRESS: STREET 1: 1359 BROADWAY, SUITE 1710 CITY: NEW YORK STATE: NY ZIP: 10018 FORMER COMPANY: FORMER CONFORMED NAME: Zentalis Pharmaceuticals, LLC DATE OF NAME CHANGE: 20200107 FORMER COMPANY: FORMER CONFORMED NAME: Zeno Pharma, LLC DATE OF NAME CHANGE: 20171212 4 1 wf-form4_165938928345083.xml FORM 4 X0306 4 2022-08-01 0 0001725160 Zentalis Pharmaceuticals, Inc. ZNTL 0001863130 Paul Andrea C/O ZENTALIS PHARMACEUTICALS, INC. 1359 BROADWAY, SUITE 1710 NEW YORK NY 10018 0 1 0 0 General Counsel Stock Option (Right to Buy) 28.82 2022-08-01 4 A 0 290500 0 A 2032-07-31 Common Stock 290500.0 290500 D The options were granted by the Issuer under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan as an inducement material to the Reporting Person's entering into employment with the Issuer in accordance with Nasdaq Listing Rule 5635(c)(4). The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer. /s/ Andrea Paul 2022-08-01